多模态影像生物标志物在卵巢肿块鉴别诊断中的应用:常规与分子影像的整合
回顾性纳入307例单侧或双侧卵巢肿块且无恶性辅助征象的患者,比较良性肿瘤、交界性卵巢肿瘤与恶性肿瘤的SULpeak,并在训练队列(n=200)与验证队列(n=131)中确定鉴别良性与交界性肿瘤同恶性肿瘤的SULpeak截断值,分析SULpeak、O-RADS MRI评分、增强CT及多模态联合的诊断效能。
要点
- 恶性肿瘤SULpeak显著高于良性肿瘤或交界性卵巢肿瘤(P<0.05)。
- 良性肿瘤与交界性卵巢肿瘤之间SULpeak无显著差异(P=0.147)。
- 鉴别良性/交界性与恶性肿瘤的SULpeak截断值为1.76(敏感度87.0%,特异度83.0%)。
核心结论
- 包含FDG PET/CT与MR/增强CT的多模态影像生物标志物可为卵巢肿块鉴别提供额外信息。
研究设计与样本
- 回顾性纳入307例单侧或双侧卵巢肿块且无恶性辅助征象、术前接受FDG PET/CT和/或MRI/增强CT的患者,以最终病理为标准。
- 在训练队列(n=200)与验证队列(n=131)中确定SULpeak截断值。
主要发现
- 恶性肿瘤SULpeak显著高于良性肿瘤或交界性卵巢肿瘤(P<0.05)。
- 良性肿瘤与交界性卵巢肿瘤之间SULpeak无显著差异(P=0.147)。
- SULpeak截断值1.76鉴别良性/交界性与恶性肿瘤的敏感度87.0%、特异度83.0%。
- O-RADS MRI鉴别良性/交界性与恶性肿瘤的敏感度100%、特异度43%。
- 增强CT鉴别良性/交界性与恶性肿瘤的敏感度94%、特异度46%。
关键数值与推荐
- SULpeak截断值1.76用于鉴别良性/交界性卵巢肿瘤与恶性肿瘤(敏感度87.0%,特异度83.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim is to investigate the diagnostic performance of multimodal imaging with 18F-FDG PET/CT, MRI, and contrast-enhanced CT (CECT) in cases with unilateral or bilateral ovarian mass without ancillary findings of malignancy. METHODS: Retrospectively, 307 patients who had unilateral or bilateral ovarian masses and underwent preoperative FDG PET/CT and/or MRI/CECT were included. The criterion standard for the ovarian mass was the final pathology. The peak standardized uptake value (SULpeak) among benign tumors (BTs), borderline ovarian tumors (BoTs), and malignant ovarian tumors (MTs) were compared. The cutoff value of SULpeak to discriminate between BT/BoT and MT was determined from the training (n = 200) and validation (n = 131) cohorts. Diagnostic performances of SULpeak, Ovarian-Adnexal Reporting Data System (O-RADS) MRI score, CECT findings, and combination of multimodal imagings were analyzed. RESULTS: SULpeak of MT was significantly higher than that of BT or BoT (P < 0.05). There was no significant difference in SULpeak between BT and BoT (P = 0.147). The cutoff value of SULpeak for discriminating between BT/BoT and MT was 1.76 (sensitivity, 87.0%; specificity, 83.0%). Diagnostic performance for BT/BoT versus MT of O-RADS MRI, CECT, FDG PET/CT plus O-RADS MRI score, and FDG PET/CT plus CECT yielded the respective sensitivities of 100%, 94%, 95%, and 82%, and specificities of 43%, 46%, 88%, and 91%, respectively. CONCLUSIONS: Multimodal imaging biomarkers including FDG PET/CT and MR/CECT could provide additional information to differentiate ovarian masses.
引用
- Bang JI, Kim JY, Choi MC, et al. Application of Multimodal Imaging Biomarker in the Differential Diagnosis of Ovarian Mass: Integration of Conventional and Molecular Imaging. Clin Nucl Med. 2022. PMID: 35006105. doi:10.1097/RLU.0000000000004008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。